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ABBREVIATIONS PAGE 
BMI, body mass index 
CIT, cold ischaemic time 
DCD, donation after circulatory death 
HCC, hepatocellular carcinoma 
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HR, hazard ratios 
MELD, Model for End-Stage Liver Disease 
NHSBT, National Health Service Blood and Transplant 
UKELD, United Kingdom Model for End-Stage Liver Disease  
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ABSTRACT 
Background: Patients who receive a liver transplant for hepatocellular carcinoma (HCC) often 
receive poorer quality livers. Tumour recurrence also has a negative effect on post-transplant 
outcomes. We compared mortality of HCC and non-HCC recipients in different post-transplant 
time periods ('epochs') to separate the impact of these different risk factors on short and longer 
term post-transplant survival. 
Methods: We identified a population-based cohort of first-time liver transplant recipients (aged 
≥ 16 years) between 2008 and 2016 in the UK. We used Cox regression to estimate hazard 
ratios (HR) comparing post-transplant mortality between HCC and non-HCC patients in three 
post-transplant epochs: 0 to 90 days, 90 days to 2 years, and 2 to 5 years, with adjustment first 
for recipient and later also for donor characteristics. 
Results: 1 270 HCC and 3 657 non-HCC transplant recipients were included. 5-year post-
transplant survival was 74.5% (95%CI 71.2% to 77.5%) in HCC patients and 84.6% (83.0% to 
86.1%) in non-HCC patients. With adjustment for recipient characteristics only, mortality of 
HCC patients was lower but not statistically significantly different in the first 90-days (HR 
0.76, 95% CI 0.53-1.09, p=0.11), but significantly higher thereafter (90 days to 2 years: HR 
1.99, 1.48-2.66, P<0.001; 2 to 5 years HR 1.77, 1.30-2.42, p<0.001). Further adjustment for 
donor characteristics had little impact on these results. 
Conclusions: HCC recipients have poorer 5-year post-transplant survival than non-HCC 
recipients, most likely because of tumour recurrence. The more frequent use of poorer quality 
donor organs for HCC does not explain this difference. 
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INTRODUCTION 
The rising incidence of hepatocellular carcinoma (HCC) has led to a marked increase in 
the number of patients with HCC receiving a liver transplant.
1
 This has put pressure on 
transplantation services in many countries as they struggle to cope with transplanting 
patients with HCC in an acceptable oncological time frame given the limited availability 
of donor organs.
1
 In response, livers with sub-optimal donor characteristics are 
increasingly being used.
2 
 
It is unknown to what extent the increase in the number of liver transplants for HCC and 
the related increased use of marginal livers have affected post-transplantation outcomes. 
International consensus recommendations only indicate that post-transplant outcomes of 
patients transplanted for HCC should be ‘comparable’ to those transplanted for non-HCC 
indications.
3
 
A study including patients transplanted between 1988 and 2003 in a number of European 
countries suggested that post-transplant survival immediately after transplantation is often 
better in patients transplanted for HCC compared to those who had liver transplant for 
other reasons.
4,5
 However, survival in HCC patients can deteriorate later during follow-up, 
most likely as a result of tumour recurrence. It has been argued that the introduction of the 
‘Milan’ criteria – a set of tumour characteristics introduced in the late 1990s to identify 
HCC patients in whom liver transplantation may provide curative treatment (one lesion 
with a diameter ≤ 5 cm, or alternatively three lesions each with a diameter ≤ 3 cm) – will 
have reduced tumour recurrence and in that way will have cancelled the reversal of HCC’s 
impact on post-transplant outcomes.
5-7 
There has been no recent large-scale study that has 
empirically tested this assertion.  
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In the UK, the Milan criteria for listing patients with HCC for liver transplantation were 
expanded in response to studies that suggested that less restrictive criteria would not 
negatively affect cancer recurrence rates and post-transplant survival.
8,9
 As a result, a set of 
expanded criteria were formally accepted in the UK in 2008 (one lesion with a diameter ≤ 5 
cm, or up to five tumours each with diameter ≤3 cm, or one lesion with a diameter >5 cm 
and ≤7 cm with no evidence of tumour progression, extrahepatic spread or new nodule 
formation over a 6-month period).
10,11
 
Our aim was to examine the prognostic impact of HCC over different time periods 
(‘epochs’) after liver transplantation using recent data from the Standard National Liver 
Transplant Registry. To correlate with the introduction of expanded selection criteria, our 
analysis focused on a cohort of patients who received a liver transplant between 2008 and 
2016. We investigated whether the impact of HCC varied over three epochs of follow-up: 
patient survival up to 90 days was chosen to reflect the occurrence of surgical 
complications, primary non-function and acute rejection,
12 
survival between 90 days and 2 
years and between 2 and 5 years to reflect tumour recurrence and chronic rejection
3,7,12,13
 
These results were first adjusted for recipient characteristics and in a second step also for 
donor characteristics to investigate the impact that the use of livers with sub-optimal donor 
characteristics has on differences in post-transplant survival between HCC and non-HCC 
recipients. In a series of sensitivity analyses, we also tested whether the effect of HCC on 
mortality differed according to a previous diagnosis of hepatitis C (HCV) and more 
specifically, whether mortality from tumour recurrence differed according to the use of 
DCD donors.  
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MATERIALS AND METHODS 
Standard National Liver Transplant Registry 
Since 1968, the Standard National Liver Transplant Registry contains information about all 
liver transplants done in the six liver transplant centers in England and one centre in Scotland. 
The dataset is managed by National Health Service Blood and Transplant (NHSBT),
14
 and 
regular checks indicate that the data are consistently more than 93% complete and accurate and 
results from several studies confirm the validity of the dataset.
14-17
 
Study population 
The study population included all recipients aged 16 years or older who received a first 
elective orthotopic liver transplant in the UK between 1
st
 January 2008 and 31
st
 December 
2016. The diagnostic category of each patient was identified from the three diagnostic fields 
available in the Standard National Liver Transplant Registry and patients were categorised into 
two groups, patients transplanted with HCC and patients transplanted with other liver disease 
diagnosis according to their primary liver diagnosis at the time of transplantation (non-HCC 
patients). In the event of multiple diagnoses, patients were considered to have HCC if HCC was 
mentioned in any of three diagnosis fields. There was no information in the UK transplant 
registry on explant pathology.  
To limit heterogeneity of the study cohort, patients who underwent transplantation for 
types of liver cancer other than HCC and those who underwent multi-visceral, super-
urgent, domino or living-related liver transplantations were excluded as well as those who 
received a liver transplant for acute liver failure (including auxiliary transplantation). We 
also excluded patients whose survival data was missing. 
Donor and recipient characteristics, primary cause of death were compared between HCC 
and non-HCC recipients. Recipient’s lifestyle activity was assessed using a 5-point scale 
ranging from ‘able to carry out normal activity without restriction’ to ‘completely reliant 
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on nursing/medical care’)17 and UKELD was used to score the severity of the liver 
disease.
18
 Cold ischaemic time was defined as the duration between start of cold perfusion in 
the donor to start of blood flow through the organ in the recipient.
19
 Values for ethnicity were 
grouped into white and non-white groups. 
Statistical Analysis 
To describe the prognostic impact of HCC, we included patients who received a liver 
transplant over a 9-year period between 1
st 
January 2008 and 31st December 2016. 
Categorical variables were presented as proportions and compared using chi-squared tests 
and continuous variables presented as means with standard deviations (SD) and compared 
using t-tests. Patients transplanted for non-HCC indications who were subsequently found 
to have an HCC on explant pathology were analysed on an intention-to-treat basis and 
remained in the non-HCC cohort.  
The Kaplan-Meier method was used to compare post-transplant patient and graft survival in 
HCC and non-HCC recipients and to compare post-transplant patient and graft survival in 
patients with HCC who were transplanted within the Milan criteria and those transplanted 
within the expanded criteria.  Follow-up data were available until 31
st
 December 2016. 
Patients with a functioning graft or alive at their last follow-up visit were considered to be 
censored observations. Graft loss was defined as either re-transplantation or patient death. 
Differences in survival were assessed with the log-rank test. 
We used multifactorial Cox regression to build three separate models. All models were 
designed to examine the prognostic impact of HCC status on patient survival in three separate 
epochs of follow-up time: up to 90 days after transplantation, between 90 days and 2 years, 
and between 2 and 5 years. In the first model, hazard ratios (HRs) comparing post-transplant 
survival in liver transplant recipients with and without HCC were estimated without 
adjustment for the donor and recipient characteristics. In the second model, HRs were 
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estimated with adjustment for recipient factors only, and in the final model HRs were 
estimated after adjustment for both donor and recipient factors. We performed a series of 
sensitivity analysis that first explored the effect of partitioning the epochs into post-
transplantation time-periods that included 90 days to 1 year and 1 year to 2 years and 
second determined whether the effect of HCC on mortality differed according to HCV 
status by testing the interaction between HCC and HCV. 
In all Cox models, adjustment for specific tumour characteristics were not included as 
comparisons of post-transplantation survival in HCC patients were made with a cohort 
non-HCC patients. All donor and recipient factors were selected on the basis of their 
clinical plausibility of being a risk factor for post-transplant survival.
16
 The time-
dependency of HCC as a risk factor for post-transplant survival and the interaction effect 
between HCC and HCV were tested with Wald tests.  
In the regression models in which we adjusted for donor and recipient characteristics, we 
also explored possible non-linear relationships between the recipient and donor 
characteristics measured as continuous variables and post-transplant survival, by including 
these as both linear and quadratic terms in the model. Missing patient and donor 
characteristics were imputed using chained equations creating ten complete datasets.
20
 The 
Cox regression results for each of these datasets were pooled using Rubin’s rules.20 No 
patient or donor characteristic had more than 15% of missing values. 
Stata V15 (StataCorp, College Station, Texas, USA) was used for all statistical analyses. A 
p-value < 0.05 was considered significant for each statistical analysis. 
RESULTS 
A total of 4 927 first adult elective liver transplants were performed between 2008 and 
2016, of which 1 270 liver transplants were for HCC recipients and 3 657 for non-HCC 
recipients (Figure 1). Compared to non-HCC recipients, those who received a liver 
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transplantation for HCC between 2008 and 2016 were more likely to be male, from non-
white ethnic backgrounds, and positive for HCV infection (Table 1). Despite being 
significantly older at the time of transplantation, HCC patients were physically more active 
(according to their recorded lifestyle activity), had better liver function (exhibited by lower 
UKELD scores), and were less likely to show signs of end-stage liver disease (varices, 
encephalopathy, and ascites). They were also less likely require ventilation or hospital 
admission immediately prior to transplantation and less likely to have undergone 
previous abdominal surgery. Patients with HCC received more grafts from organs 
donated following circulatory death (DCD), or grafts in which the appearance had been 
documented as ‘abnormal’ or ‘steatotic’. CIT was marginally lower in HCC recipients 
and there were only small differences between the cohorts in the frequency of capsular 
damage in the donor organ. Of the 1 270 HCC recipients who were included in our 
study, only 81 (6.4%) had tumour characteristics that were beyond the Milan but 
within the expanded criteria at the time of registration on the transplant waiting list. 
Kaplan-Meier survival curves comparing outcomes in HCC and non-HCC patients showed 
that patient and graft survival in the first months following liver transplantation is very 
similar (Figure 2). After about three to four months, HCC patients seem to have 
progressively worse patient survival, resulting in a 5-year patient survival of 74.5% 
(95%CI 71·2 to 77·5%) for HCC patients and 84·6% (95%CI 83·0 to 86·1%, P<0.001) for 
non-HCC patients. A similar time pattern was observed for prognostic impact of HCC on 
graft survival with corresponding 5-year estimates of 70·2% (95%CI 66·8 to 73·3%) for 
HCC patients and 79·1% (95%CI 77·4 to 80·7%, p<0.001) for non-HCC patients. 
We did not find a difference in the 5-year patient survival between the 1 189 HCC patients 
who met the Milan criteria (74·6%, 95%CI 71·1% to 77·7%) and the 81 who did meet the 
expanded criteria (74·5%, 95%CI 58·6% to 85·0%; p=0·76; figure 3). Neither did we find 
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
11 
 
differences in graft survival between these patient groups (70·4%, 95%CI 67·0% to 73·6% 
and 67·8%, 95%CI 55·2% to 79·3%, respectively p=0·81). 
The first Cox regression model, comparing HCC and non-HCC patients without 
adjustment for donor or recipient characteristics, did not find a statistically significant 
difference in survival in the first 90 days following transplantation (HR 0.88 CI; 0.63-1.23, 
Table 2). In the subsequent two epochs of follow-up time, patients with HCC had a 
significantly poorer survival (HR 2.27 between 90 days and 2 years and HR 2.00 between 
2 and 5 years). In the second Cox regression model, only adjusting for recipient 
characteristics did not dramatically change the impact of HCC on survival in either the 
first 90 days following transplantation (adjusted HR 0.76 CI; 0.53-1.09) or in the two later 
epochs of follow-up time (adjusted HR 1.99 between 90 days and 2 years and adjusted HR 
1.77 between 2 and 5 years). In the third Cox model, additional adjustment for donor 
characteristics also had little effect on the impact of HCC in each of the epochs of follow-
up time (adjusted HR 0.74 between 0-90 days, adjusted HR 1.96 between 90 days and 2 
years and adjusted HR 1.74 between 2 and 5 years).  The results of the Cox regression 
analysis of graft survival (Table 3) closely mirrored the results found for patient survival 
(Table 2).  
In the sensitivity analysis that explored the impact of HCC in four separate epochs, we 
found that it was highest between 90 days and 1 year after transplantation (adjusted HR: 
2.10 95%CI: 1.47 to 3.00) and that it remained at a very similar level thereafter (Table S5, 
SDC, http://links.lww.com/TP/B665). The sensitivity analysis testing the interaction 
between HCC and HCV status did not show that the effect of HCC on mortality differed 
significantly according to HCV status (HCV+ve HR 1.16, 0.87-1.56, HCV-ve HR; 
0.86,0.64-1.15, p for interaction =0.10). 
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In the first 90 days following transplantation, there were no statistically significant differences 
in the distribution of cause of death between HCC and non-HCC recipients and no patient died 
from tumour recurrence (recurrence of malignant primary disease; Table 4). In the subsequent 
post-transplant epochs, tumour recurrence in HCC recipients became a more frequent cause of 
death accounting for 23 of the 101 deaths (22.7%) between 90 days and 2 years and 12 of the 
77 deaths (15.6%) between 2 and 5 years. When splitting cause of death into four epochs we 
found that from 90 days onwards the number of patients dying from tumour recurrence 
remained more or less constant (Table S6, SDC, http://links.lww.com/TP/B665). 
Of the 35 HCC recipients who died of tumour recurrence, nine (25.7%) had received a DCD 
liver compared 396 of the 1235 other HCC recipients (32.1%; p=0.43) which demonstrates that 
there is no evidence that the use of DCD livers is linked to an HCC recurrence risk. The 
proportion of patients who died from malignancies other than tumour recurrence was higher in 
the HCC recipients (2.9% or 37/1270) than in non-HCC recipients (1.1% or 41/3657) and this 
difference was most prominent in deaths from non-lymphoid malignancies (Table 4). Overall, 
recurrence of benign primary disease, which includes HCV, was infrequently reported as a 
cause of death (Table 4 and see Table S6, SDC, http://links.lww.com/TP/B665), irrespective of 
HCC status at the time of transplant or epoch of follow-up (Table 4 and see Table S6, SDC, 
http://links.lww.com/TP/B665). 
DISCUSSION 
Summary of results 
At the time of transplantation, HCC patients were on average in a better physical condition and 
had less signs of end-stage liver disease than non-HCC patients, but they received more often 
‘sub-optimal’ grafts. We found that survival of HCC and non-HCC recipients was similar in the 
first months after transplantation. Then survival of HCC recipients deteriorated with the rate of 
mortality and graft failure being at least 50% higher than in non-HCC recipients, with tumour 
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recurrence as the most important explanation. The difference in survival could not be explained 
by HCC recipients receiving a higher proportion of livers from DCD donors or from donors 
with other sub-optimal characteristics.  
Methodological limitations 
The key limitation of our analysis is that we used pre-defined post-transplant epochs (up to 90 
days, between 90 days and 2 years, and between 2 and 5 years) to investigate the time-
dependency of the impact of HCC on patient and graft survival. This approach assumes 
that the prognostic impact of HCC on survival is constant within each of these epochs.
21
 
The advantage of this approach is that the hazard ratios can be estimated using standard 
Cox regression methods and, more importantly, that the results are relatively easy to 
interpret. Its disadvantage is that the partitioning of the survival time in distinct epochs 
needs to be chosen in advance and that the number of separate epochs as well as their 
duration is arbitrary. 
In our analysis, we compared HCC patients with a heterogeneous cohort of non-HCC 
patients. This approach may have masked specific survival patterns of individual primary 
liver diseases. However, the dichotomy in HCC and non-HCC patients reflects the 
difference in how HCC and non-HCC were selected for transplantation in the UK. Whilst 
for most non-HCC patients the urgency of transplantation was taken from their liver 
function according to the UKELD score, the urgency for HCC patients came from the need 
to avoid cancer progression before transplantation. 
Comparison with other studies 
We studied the prognostic impact of HCC on post-transplant survival in three distinct epochs, 
aiming to capture on the one hand that HCC patients are in a better physical condition at the 
time of transplantation – which may give them better surgical outcomes – but on the other that 
tumour recurrence may deteriorate survival in the later stages. Already 30 years ago, the 
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importance of analysing liver transplant outcomes in epochs of follow-up time was recognised, 
but this statistical approach is very rarely practised.
4,22
 Our study is an example of how 
important it is to analyse post-transplant outcomes in distinct epochs of follow-up time, guided 
by an understanding of the relevant underlying clinical mechanisms. For example, risk factors 
for immediate surgical outcomes are predominantly linked to the recipients’ physical condition 
and risk factors for longer term outcomes to recurrence of the original disease that was the 
reason for transplantation.  
It was expected that the introduction of the Milan criteria would lead to a decrease in recurrence 
rates in patients transplanted for HCC.
4
 However, our study, which reflects outcomes of modern 
liver transplantation practice, including a national population-based cohort of patients 
transplanted between 2008 and 2016, indicates that tumour recurrence remains an important 
risk factor for survival in the later stages after liver transplantation, which corresponds with 
earlier reports of post-transplant survival.
1-3 
Despite a formal adoption of expanded HCC selection criteria in 2008, we found that only 6·4% 
of HCC recipients were selected for transplantation within these expanded criteria and we could 
not demonstrate differences in post-transplant outcomes compared to those who were selected 
according to the Milan criteria. Reasons for why only a very small minority of HCC recipients 
were transplanted beyond the Milan criteria are difficult to explain and we must acknowledge 
that this analysis does not specifically address this question. However, a tendency for 
radiological assessment to understage some HCC patients prior to transplantation may have 
prohibited the aggressive use of the extended selection criteria, especially when other studies 
have indicated a linear relationship between tumour burden and post-transplantation 
survival.
23,24
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Explanation of results 
Our study found that HCC patients were more likely to receive sub-optimal donor organs with 
characteristics previously proven to have poorer post-transplant outcomes.
2
 This included 
donated livers that were either steatotic, abnormal in appearance, or that were from DCD 
donors. However, our analysis was specifically designed to test the impact of donor 
characteristics on post-transplant survival and we observed that additional adjustment for donor 
characteristics had little effect on the differences in survival between HCC and non-HCC 
recipients in any of the epochs following transplantation.  
The incidence of HCV recurrence following transplantation is also an unlikely explanation for 
the observed differences in survival. Previous studies have reported that, irrespective of HCC 
status at the time of transplantation, survival between those with and without HCV is similar up 
to 5-years following transplantation and worse thereafter.
25,26 
In our own analysis, we did not 
find the effect of HCC on mortality to differ significantly according to whether the patient had a 
previous a diagnosis of HCV nor did we find HCV recurrence to be frequently reported as a 
cause of death in the first five years after transplantation.  
Similarly, differences in the incidence of acute rejection do not explain the differences in the 
survival patterns of HCC and non-HCC recipients. In efforts to reduce the risk of tumour 
recurrence, HCC recipients can be subjected to more conservative immunosuppression 
protocols
27
 and therefore they may be at an increased risk of acute rejection. However, we have 
found that 1-year readmissions for acute rejection in patients transplanted in the UK between 
2008 and 2016 occurred less frequently in HCC recipients (2.8% Or 35/1270) than in non-HCC 
recipients (3.1% Or 112/3657, p=0.57) whilst acute rejection recorded as a cause of death was 
not identified at all within the study cohort (London School of Hygiene and Tropical Medicine, 
unpublished observations). 
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We identified some differences in the proportion of HCC and non-HCC recipients who died of 
malignancies other than tumour recurrence. This cause of death, particularly non-lymphoid 
related malignancies, were more frequent in HCC recipients and consistent with existing 
literature there was a high incidence between 3 months and two-years after transplantation.
28
 
However, the differences in the overall number of HCC and non-HCC recipients who died from 
malignancies other than tumour recurrence were too small to fully explain the differences in 
survival between the two cohorts.  
Beyond 90 days, differences in survival are best explained by differences in deaths due to 
tumour recurrence and this remained so even when we further partitioned the follow-up period 
to include survival from 90 days to 1 year and from 1 year to 2 years. Of the HCC patients who 
were recorded to have died of tumour recurrence within 1-year, only one was pre-operatively 
staged according to the extended criteria with other early deaths potentially explained by 
aggressive tumour biology and or radiological understaging of the HCC prior to 
transplantation.
13 
In further analysis, we did not find the use of DCD livers to be associated with 
an increased risk of death from tumour recurrence. 
In the past, HCC patients were found to have 90-day outcomes that were statistically 
significantly better than non-HCC patients.
5
 Our results suggested that 90-day outcomes of 
HCC patients were better but the difference with non-HCC patients was not statistically 
significant. One important explanation for not finding a significant difference is the substantial 
improvement in post-transplant outcomes in the last 30 years which considerably reduces the 
statistical power to detect differences.
29 Another explanation is that the impact of recipients’ 
frailty at the time of transplantation has decreased given the improvements in peri-operative 
care and the high-dependency care immediately after transplantation.
30 
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Implications of findings 
Our results demonstrate that outcomes in patients transplanted for HCC are worse than in those 
transplanted for non-HCC indications. This is not explained by the fact that we are using more 
DCD donors in HCC patients or that we are transplanting a significant proportion of patients 
who, at the time of transplantation, are beyond the Milan criteria. Instead we must acknowledge 
that even with the stringent adoption of the Milan criteria in the UK, we are still selecting for 
transplantation a significant proportion of patients with HCC who are at risk of tumour 
recurrence. Therefore, until we can add to our selection criteria new parameters that better 
predict tumour recurrence, the poorer survival of HCC patients after liver transplantation will 
remain. 
Until recently, many guidelines stipulated that patients with HCC should only receive a liver 
transplant if their predicted outcomes are ‘comparable’ to non-HCC patients.3 However, in the 
last decade this has never been the case. This has been recognised by the service providers and 
donor liver allocation schemes are now moving towards using criteria based on transplant 
‘benefit’ – in which they aim to maximise the net life years gained from the point of registration 
on the waiting rather than providing the greatest chance of surviving after transplantation.
,31,32
 
However, the decision to offer HCC patients a liver transplant is further complicated as other 
treatments, including resection and ablation, have to be considered which is all the more 
important considering the impact that an increased use of liver transplantation in HCC patients 
will have on outcomes for non-HCC patients on the waiting list for transplantation given the 
ongoing donor organ shortage.
1,3
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CONCLUSION  
Between 2008 and 2016, almost all HCC patients who received a liver transplant in the UK 
met the Milan criteria. Nevertheless, one in four HCC recipients died within five years 
compared to only one in six non-HCC patients, with tumour recurrence being the most 
likely explanation for this difference. These differences could not be explained by the 
increased use of poorer quality donor organs in HCC patients. Donor allocation schemes 
based on transplant benefit schemes are likely to accommodate the poor post-transplant survival 
of HCC patients given their greater net gain in post-transplanted expected life years. 
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FIGURES 
Figure 1: Flow chart detailing selection of study population (2008-2016). 
Figure 2: Five-year patient and graft survival stratified by HCC status 2008-2016 (n=4 
927). 
Figure 3: Five-year patient and graft survival for HCC patients stratified by type of 
selection criteria  2006-2016 (n=1 270). 
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Table 1: Donor and recipient patient characteristics (n= 4927) 
Indication Group HCC Non-HCC   
Number N = 1 270 N = 3 657 Missing values P value 
DONOR  % / N % / N N  
 
Sex Female 42·8% (544) 47·6% (1 740) 0  0·003 
     
Cause of death Trauma 9·1% (115) 7·7% (281)   
 
0·21 
 CVA 62·6% (796) 64·8% (2 371)  
 Others 28·3% (359) 27·5% (1 005) 0 
      
Donor Type DCD 31·9% (405) 21·2% (774) 0 <0·001 
      
ABO Match Identical 98·0% (1 245) 98·6% (3 606)   
 
0·34  
Compatible 1·9% (24) 1·3% (48)  
 Incompatible 0·1% (1) 0·1% (3) 0 
      
Graft Type Segmental 6·0% (76) 8·9% (324) 0 0·001 
      
Organ appearance Abnormal 29·8% (308) 22·8% (709) 776 <0·001 
      
Steatosis Presence 48·2% (604) 44·6% (1 603) 84 0·03 
      
Capsular damage Presence 14·3% (178) 14·1% (507) 92 0·91 
      
Donor age, years Mean (SD) 50 (16) 49 (16) 0 0·07 
      
Donor BMI, kg/m
2
 Mean (SD) 27 (5·0) 26 (5·0) 10 0·15 
      
Cold Ischaemic Time (mins) Mean (SD) 502 (158) 517 (158) 392 0·01 
RECIPIENT     
Sex Female 19·8% (251) 37.3% (1 363) 1 < 0·001 
    
Recipient ethnicity Non-White 16·5% (209) 11.1% (407) 2 < 0·001 
    
HCV status Positive 42·6% (509) 12.1% (418) 285 < 0·001 
    
Pre-transplant in patient status Inpatient 4·9% (62) 16.6% (608) 6 < 0·001 
    
Ascites Presence 29·8% (378) 61.8% (2 251) 17 < 0·001 
    
Encephalopathy Presence 15·2% (189) 36.1% (1 300) 82 < 0·001 
    
Pre-transplant renal support Yes 4·7% (60) 4.6% (170) 13 0·9 
    
Pre-transplant ventilation 
requirement 
Yes 0.2% (3) 0.9% (31) 8 0.02 
     
Previous abdominal surgery Yes 10·0% (127) 12.4% (453) 17 0·02 
    
Previous variceal bleed Presence 15·7% (199) 27.4% (1002) 56 < 0·001 
    
Life style activity Normal 12·9% (161) 3.8% (139)  < 0·001 
Restricted 44·2% (554) 31.5% (1 136)  
Self-care 37·4% (469) 47.7% (1 724)  
Reliant 4·5% (56) 14.0% (505)  
Confined 1·0% (13) 3.0% (107) 63 
 
Age (years) Mean (SD) 58 (8·0) 51 (11.8) 0 < 0·001 
      
BMI, Kg/m2 Mean (SD) 28 (4·8) 27 (5.3) 5 < 0·001 
      
UKELD Mean (SD) 51 (4·9) 56 (5.4) 38 < 0·001 
*No data item had more than 15% of missing values*  
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Table 2: Impact of HCC on post-transplant patient survival in three separate epochs of follow-up time 
(n=4 927). 
 HCC compared to non-HCC 
Hazard ratio (95% CI) 
 
P value time 
dependency*2 
 
Post-transplant patient survival 
 
      0 to 3 months 
 
 
3 to 24 months 
 
24 to 60 months 
 
 
Unadjusted analysis 
 
0·88 (0·63-1·23) 
 
2·27 (1·74-2·94) 
 
2·00 (1·50-2·66) 
 
<0·001 
     
Adjusted for recipient characteristics*1 0·76 (0·53-1·09) 1·99 (1·48-2·66) 1·77 (1·30-2·42) <0·001 
     
Adjusted for recipient and donor 
characteristics*1 
0·74 (0·52-1·07) 1.96 (1·46-2·62) 1·74 (1·27-2·31) <0·001 
     
*1 Adjusted for a) Recipient characteristics: sex, ethnicity, HCV status, pre-transplant inpatient status, ascites, encephalopathy, pre-
transplant renal support, previous abdominal surgery, varices, lifestyle activity, age, BMI (Kg/M2), UKELD and b) Donor characteristics: 
sex, cause of death, donor type (donation after cardiac death or donation after brain death), ABO match, graft type, organ appearance, 
steatosis, capsular damage, age, BMI (Kg/m2), cold ischaemic time.  
*2 P-values represent whether HR’s in each epoch of follow-up time differ significantly from each other.  
*3 Tables S1 and S2, SDC, http://links.lww.com/TP/B665 in the supplemental information have HRs and 95% CI for all other donor and 
recipient characteristics.  
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Table 3: Impact of HCC on post-transplant graft survival in three separate epochs of follow-up time   
(n=4 927). 
 HCC compared to non-HCC 
Hazard ratio (95% CI) 
 
P value time 
dependency*2 
 
Post-transplant graft survival 
 
     0 to 3 months 
 
 
3 to 24 months 
 
24 to 60 months 
 
 
Unadjusted analysis 
 
0·95 (0.75-1.21) 
 
1·84 (1.46-2.34) 
 
1·82 (1·38-2·39) 
 
<0·001 
     
Adjusted for recipient characteristics*1 0·89 (0.68-1.17) 1·74 (1.34-2.27) 1·72 (1·28-2·31) <0·001 
      
Adjusted for recipient and donor 
characteristics*1 
0·84 (0.65-1.11) 1·67 (1.28-2.17) 1·66 (1·23-2·23) <0·001 
     
*1 Adjusted for a) Recipient characteristics: sex, ethnicity, HCV status, pre-transplant inpatient status, ascites, encephalopathy, pre-
transplant renal support, previous abdominal surgery, varices, lifestyle activity, age, BMI (Kg/M2), UKELD and b) Donor characteristics: 
sex, cause of death, donor type (donation after cardiac death or donation after brain death), ABO match, graft type, organ appearance, 
steatosis, capsular damage, age, BMI (Kg/m2), cold ischaemic time. 
*2 P-values represent whether HR’s in each epoch of follow-up time differ significantly from each other.  
*3 Tables S3 and S4, SDC, http://links.lww.com/TP/B665 in the supplemental information have HRs and 95% CI for all other donor and 
recipient characteristics.  
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Table 4: Primary cause of death following liver transplantation for HCC and non-HCC patients in three 
separate epochs of follow-up time (n=620).  
Cause of Death 
 
 
 
0-90 days 91 days – 24 months 24 months – 60 months 
HCC 
(n=44) 
Non-HCC 
(n=144) 
HCC 
(n=101) 
Non-HCC 
(n=132) 
HCC 
(n=77) 
Non-HCC 
(n=122) 
Recurrent primary disease 
- malignant*1 
0% (0) 0% (0) 22.7% (23) 1.5% (2) 15.6% (12) 1.6% (2) 
 
Recurrent primary disease 
- benign*2 
2.3% (1) 0.0% (0) 1.0% (1) 3.8% (5) 1.3% (1) 2.5% (3) 
 
Malignancy -
Lymphoproliferative  
2.3% (1) 0.0% (0) 3.0% (3) 4.5% (6) 1.3% (1) 4.9% (6) 
Malignancy – Non  
Lymphoproliferative  
0.0% (0) 0.0% (0) 12.9% (13) 9.1% (12) 24.7% (19) 13.9% (17) 
 
Sepsis 45.5% (20) 42.3% (61) 24.7% (25) 37.1% (49) 22.0% (17) 29.5% (36) 
 
Graft Failure 2.3% (1) 4.2% (6) 3.0% (3) 0.8% (1) 1.3% (1) 0.8% (1) 
 
Haemorrhage 4.5% (2) 6.9% (10) 3.0% (3) 1.5% (2) 1.3% (1) 1.6% (2) 
 
Pulmonary Failure 2.3% (1) 6.3% (9) 3.9% (4) 9.9% (13) 9.1% (7) 5.8% (7) 
 
Renal Failure 0.0% (0) 0.7% (1) 0% (0) 0% (0) 0.0% (0) 0.8% (1) 
 
Cardiac Failure 9.1% (4) 9.7% (14) 3.0% (3) 6.1% (8) 1.3% (1) 6.6% (8) 
 
Hepatic Failure 2.3% (1) 0.7% (1) 0.0% (0) 1.5% (2) 2.6% (2) 1.6% (2) 
 
Gastrointestinal 0% (0) 0.7% (1) 0.0% (0) 0% (0) 1.3% (1) 1.6% (2) 
 
Infection  4.5% (2) 0.7% (1) 2.0% (2) 0% (0) 0.0% (0) 0.8% (1) 
 
CVA 4.5% (2) 3.5% (5) 0.0% (0) 2.3% (3) 1.3% (1) 2.5% (3) 
 
Other 20.4% (9) 22.2% (32) 10.9% (11) 15.9% (21) 10.4% (8) 10.7% (13) 
 
Unknown 0% (0) 2.1% (3) 9.9% (10) 6.0% (8) 6.5% (5) 14.8% (18) 
 
P-value*3 0.38 <0.001 0.03 
*1 Recurrence of malignant disease for patients transplanted for non-HCC indications likely represents recurrence of a  
    intrahepatic malignancy only identified on explant pathology or an error in the recording cause of death 
*2 Includes the recurrence of HCV and the cholestatic liver diseases (PSC and PBC). 
*3 p value of chi squared test comparing distribution of causes of death in HCC and non-HCC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
28 
 
 
  
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
29 
 
 
  
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
30 
 
 
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
